drugset
drugset / Trial / NCT00795548

Safety Study of 5-Azacitidine and Standard Donor Lymphocyte Infusion (DLI) to Treat Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing After Allogeneic Stem Cell Transplantation

NCT00795548 ↗

Phase 2 Completed 30 enrolled Heinrich-Heine University, Duesseldorf
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This open label phase-II trial evaluates hematological response of an additional treatment with 5-Azacitidine to common DLI in patients with MDS or AML relapsing after allogeneic stem cell transplantation.

Timeline

Start
2008-11
Primary completion
2010-10
Completion
2011-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Azacitidine Other / unclassified 100 mg/m2 Subcutaneous

Indications

acute myeloid leukemia myelodysplastic syndrome